[The results of the registration clinical trials of the Act-Hib vaccine manufactured by the firm of Pasteur Mérieux Connaught, France].
The results of the field trials of the vaccine "Act-Hib" against Haemophilus influenzae of type b, presented for registration by Pasteur Mérieux Connaught (France), are summarized. The vaccine was found to have low reactogenicity and high immunological effectiveness. A single injection of the vaccine induced the formation of the protective level of anti-PRP antibodies in 94% of the immunized children aged 1-4 years. After immunization the mean geometric titers of specific antibodies increased sixfold in comparison with the initial level and were equal to 3.4 mu/ml. On the basis of the data of laboratory control and field clinical trials the vaccine "Act-Hib" was registered in the Russian Federation and permission and its practical use in the public health service of the country was permitted.